At the molecular level, there are important gender differences: 95% of male breast cancer patients have luminal A or B tumors, compared with 73% of female breast cancer patients.[20] Both the basal and HER2 phenotypes are rare in men. Here, ERBB2 is linked to breast carcinoma.